Scientists test Double-Punch combo to keep advanced lung cancer in check
NCT ID NCT04748419
Summary
This study is testing whether adding a short, intense course of radiation (called a 'boost') to a standard immunotherapy drug (durvalumab) is safe and more effective for controlling stage III non-small cell lung cancer. The treatment is for patients who have already completed standard chemotherapy and radiation. The main goals are to see if the combination is safe and if it helps keep the cancer from growing for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.